Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 4, 1999, Pages 436-439

  Favreau, Leonard V ^a   Palamanda, Jairam R ^a   Lin, Chin Chung ^a   Nomeir, Amin A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN; DEBRISOQUINE 4 HYDROXYLASE; DEXTROMETHORPHAN; ERYTHROMYCIN; IMIPRAMINE; KETOCONAZOLE; PROPRANOLOL; QUINIDINE; RECOMBINANT ENZYME; TRIFLUPERIDOL; TROLEANDOMYCIN;

ARTICLE; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP2D6; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032893695     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Chen ZR, Somogyi AA and Bochner F (1990) Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit 12: 97-304.
2. Crespi CL, Miller VP and Penman PW (1997) Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450. Anal Biochem 248:188-190.
3. Gonzalez F (1989) The molecular biology of cytochrome P450s. Pharmacol Rev 40:243-288.
4. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450 (Ortiz-de Montellano PR ed.) pp 473-535. Plenum Press, New York.
5. Guengerich FP (1996) In vitro techniques for studying drug metabolism. J Pharmacokinet Biopharm 24:521-533.
6. Halliday RC, Jones BC, Smith DA. Kitteringham NR and Park BK (1995) An investigation of the interaction between halofantrine. CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369-378.
7. Lewis DFV, Eddershaw PJ, Goldfarh PS and Tarbit MH (1997) Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27:319-340.
8. Nielson F. Rosholm JU and Brøsen K (1995) Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism. Eur J Clin Pharmacol 48:501-504.
9. Palamanda JR, Favreau LV, Lin CC and Nomeir AA (1998) Validation of a rapid microtiter plate assay to conduct cytochrome P4502D6 enzyme inhibition studies. Drug Discovery Today 3:466-470.
10. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:45-57.
11. Rodrigues AD and Roberts EM (1997) The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos 25:651-655.
12. Shimada T, Yamazaki H, Mimuni M. Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes from 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
13. Shimada T, Yamazaki H, Mimura M. Wakamiya N. Ueng YF, Guengerich FP and Inui Y (1996) Characterisation of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515-522.
14. Spatzenegger M and Jaeger W (1995) Clinical importance of hepatic cytochrome P450s in drug metabolism. Drug Metab Rev 27:397-417.